These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38289453)

  • 1. Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem.
    Abrignani MG; Gronda E; Marini M; Gori M; Iacoviello M; Temporelli PL; Benvenuto M; Binaghi G; Cesaro A; Maloberti A; Tinti MD; Riccio C; Colivicchi F; Grimaldi M; Gabrielli D; Oliva F;
    Cardiovasc Drugs Ther; 2024 Jan; ():. PubMed ID: 38289453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy.
    Murphy D; Banerjee D
    Curr Heart Fail Rep; 2022 Aug; 19(4):191-199. PubMed ID: 35704263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New frontiers for management of hyperkalaemia: the emergence of novel agents.
    Nassif ME; Kosiborod M
    Eur Heart J Suppl; 2019 Feb; 21(Suppl A):A34-A40. PubMed ID: 30837803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate.
    Rosano GMC; Spoletini I; Agewall S
    Eur Heart J Suppl; 2019 Feb; 21(Suppl A):A28-A33. PubMed ID: 30837802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches to management of hyperkalaemia in kidney transplantation.
    Rizk J; Quan D; Gabardi S; Rizk Y; Kalantar-Zadeh K
    Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):27-37. PubMed ID: 33027094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of a Bespoke Hyperkalaemia Clinic to Facilitate Prescribing of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction.
    Ali I; Green D; Kalra P; Kalra PA
    Cardiorenal Med; 2022; 12(5-6):196-204. PubMed ID: 36044877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease.
    Rossignol P; Silva-Cardoso J; Kosiborod MN; Brandenburg V; Cleland JG; Hadimeri H; Hullin R; Makela S; Mörtl D; Paoletti E; Pollock C; Vogt L; Jadoul M; Butler J
    Pharmacol Res; 2022 Aug; 182():106277. PubMed ID: 35662631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia:
    Rossignol P; Pitt B
    Clin Kidney J; 2023 Aug; 16(8):1221-1225. PubMed ID: 37529653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatments for hyperkalaemia: clinical use in cardiology.
    Vijayakumar S; Butler J; Anker SD
    Eur Heart J Suppl; 2019 Feb; 21(Suppl A):A41-A47. PubMed ID: 30837804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology.
    Rossignol P
    Eur Heart J Suppl; 2019 Feb; 21(Suppl A):A48-A54. PubMed ID: 30837805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperkalaemia in Heart Failure.
    Ismail U; Sidhu K; Zieroth S
    Card Fail Rev; 2021 Mar; 7():e10. PubMed ID: 34094588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In pursuit of balance: renin-angiotensin-aldosterone system inhibitors and hyperkalaemia treatment.
    Sciatti E; D'Elia E; Balestrieri G; D'Isa S; Iacovoni A; Senni M
    Eur Heart J Suppl; 2023 May; 25(Suppl C):C301-C305. PubMed ID: 37125304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium/calcium polystyrene sulfonate.
    Onogi C; Watanabe Y; Tanaka A; Furuhashi K; Maruyama S
    Clin Kidney J; 2024 Feb; 17(2):sfae021. PubMed ID: 38404365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland.
    Ward T; Brown T; Lewis RD; Kliess MK; de Arellano AR; Quinn CM
    Pharmacoecon Open; 2022 Sep; 6(5):757-771. PubMed ID: 35925491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives.
    Llubani R; Vukadinović D; Werner C; Marx N; Zewinger S; Böhm M
    Curr Heart Fail Rep; 2018 Dec; 15(6):390-397. PubMed ID: 30421355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of potassium-binder patiromer for up-titration of renin-angiotensin-aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report.
    Jiménez-Marrero S; Enjuanes C; Yun S; Comín-Colet J
    Eur Heart J Case Rep; 2020 Aug; 4(4):1-4. PubMed ID: 32974448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.